## Condensed Consolidated Statement of Cash Flows - Unaudited

| For the six months ended 30 June  | 2018<br>US\$ m  | 2017<br>US\$ m  |
|---|-----------------|-----------------|
| Profit before taxation  | 545.6           | 536.2           |
| Adjustments for:  |                 |                 |
| Finance costs   | 195.4           | 169.0           |
| Depreciation  | 159.7           | 131.2           |
| Amortization of intangible assets   | 49.5            | 46.3            |
| Provision/(reversal of provision) for onerous contracts, net  | 3.7             | (3.5)           |
| Employee share-based compensation benefit expenses Provision for impairment losses  | 2.4<br>1.7      | 6.3<br>21.7     |
| Loss on changes in fair value of biological assets  | 0.8             | 6.4             |
| Loss/(gain) on divestment of interest in an associated company  | 0.2             | (14.6)          |
| Share of profits less losses of associated companies and joint ventures   | (189.0)         | (132.7)         |
| Interest income   | (29.1)          | (26.3)          |
| Gain on remeasurement of a previously held interest in an associated company  | (4.3)           | (27.8)          |
| Gain on disposal of property, plant and equipment   | (1.1)           | (0.6)           |
| Loss on remeasurement of a previously held interest in a joint venture  | -               | 22.5            |
| Preferred share dividend income from a joint venture  | -               | (50.8)          |
| Others  | 6.8             | 11.2            |
| Increase in working capital   | 742.3<br>(69.7) | 694.5<br>(129.2 |
| Increase in working capital  Net cash generated from operations   | 672.6           | 565.3           |
| Interest received   | 32.9            | 25.2            |
| Interest paid   | (180.6)         | (152.2          |
| Taxes paid  | (126.4)         | (142.7          |
| Net cash flows from operating activities  | 398.5           | 295.6           |
| Decrease/(increase) in short-term deposits and time deposits with   |                 |                 |
| original maturity of more than three months   | 149.3           | (16.6)          |
| Dividends received from associated companies  | 136.8           | 82.2            |
| Decrease in restricted cash   | 20.5            | 12.1            |
| Proceeds from disposal of property, plant and equipment   | 19.0            | 10.2            |
| Dividends received from financial assets at fair value through assets   |                 |                 |
| other comprehensive income/available-for-sale   | 3.3             | 3.0             |
| Proceeds from divestment of interests in associated companies   | 2.5             | 248.2           |
| Proceeds from disposal of financial assets at fair value through assets   | 1.5             | 59.5            |
| other comprehensive income/available-for-sale Investments in intangible assets  | (241.1)         | (150.9)         |
| Purchase of property, plant and equipment   | (202.1)         | (319.6)         |
| Increased investments in joint ventures   | (59.0)          | (42.1)          |
| Investments in associated companies   | (50.9)          | (8.3)           |
| Partial payment for acquisition of a subsidiary company   | (46.9)          | -               |
| Acquisition of financial assets at fair value through   |                 |                 |
| other comprehensive income/available-for-sale assets  | (23.8)          | (14.1)          |
| Acquisition of subsidiary companies   | (16.2)          | (117.5)         |
| Increased investments in associated companies   | (8.7)           | (3.1)           |
| Investment in a joint venture   | (7.1)           | - (2.0)         |
| Advances to a joint venture   | (2.3)           | (3.8)           |
| Investments in biological assets  | (0.3)           | (1.4)<br>69.9   |
| Proceeds from redemption of preferred shares issued by a joint venture  Preferred share dividends received from a joint venture | -               | 31.7            |
| Disposal of a subsidiary company  | _               | 0.4             |
| Acquisition of a business   | -               | (3.8)           |
| Net cash flows used in investing activities   | (325.5)         | (164.0)         |
| Proceeds from new borrowings  | 2,070.5         | 1,386.0         |
| Capital contributions from non-controlling shareholders   | 35.0            | 3.3             |
| Proceeds from issue of shares to non-controlling shareholders by subsidiary companies   | 0.2             | 1.1             |
| Borrowings repaid   | (2,043.0)       | (1,219.3)       |
| Dividends paid to non-controlling shareholders by subsidiary companies  | (108.4)         | (67.1           |
| Distributions paid to shareholders  | (30.4)          | (30.5)          |
| Increased investments in subsidiary companies   | (27.1)          | -               |
| Payments for concession fees payable  | (13.4)          | (14.0)          |
| Payments for purchase of shares under a long-term incentive plan  | (2.0)           | 34.5            |
| Proceeds from issue of shares under a long-term incentive plan  Net cash flows (used in)/from financing activities              | (118.6)         | 94.0            |
| Net (decrease)/increase in cash and cash equivalents  | (45.6)          | 225.6           |
| Cash and cash equivalents at 1 January  | 1,987.3         | 1,611.2         |
| Exchange translation  | (105.9)         | 0.4             |
| Cash and cash equivalents at 30 June  | 1,835.8         | 1,837.2         |
| Representing  | ,               | ,               |
| Cash and cash equivalents and short-term deposits as stated in  |                 |                 |
| the condensed consolidated statement of financial position  | 1,856.4         | 2,145.4         |
| Less short-term deposits and time deposits with   |                 |                 |
| original maturity of more than three months   | (20.6)          | (308.2)         |
| Cash and cash equivalents at 30 June  | 1,835.8         | 1,837.2         |
|   |                 |                 |